Sugi Predict

Sugi Predict / Compounds / SCHEMBL336299

SCHEMBL336299

SCHEMBL336299

OC1(Cc2ccc(Cl)cc2)CCNCC1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ DRD2 P14416 2/20 0.55
▸ GRIN2D O15399 1/20 0.46
▸ GRIN3B O60391 1/20 0.46
▸ ADRA1D P25100 1/20 0.46
▸ ADRA1A P35348 1/20 0.46
▸ ADRA1B P35368 1/20 0.46
▸ GRIN1 Q05586 1/20 0.46
▸ GRIN2A Q12879 1/20 0.46
▸ GRIN2B Q13224 1/20 0.46
▸ GRIN2C Q14957 1/20 0.46
▸ GRIN3A Q8TCU5 1/20 0.46
▸ DRD4 P21917 1/20 0.45
▸ DRD3 P35462 1/20 0.45
▸ FPR2 P25090 2/20 0.43
▸ PROKR1 Q8TCW9 2/20 0.43
▸ SLC6A2 P23975 2/20 0.38
▸ SLC6A4 P31645 2/20 0.38
▸ MEN1 O00255 1/20 0.36
▸ KMT2A Q03164 1/20 0.36
▸ HTR3E A5X5Y0 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL11613923 0.98 DRD2 (0.53) DRD2GRIN2DGRIN3BADRA1DADRA1A
SCHEMBL2795835 0.89 DRD2 (0.47) DRD2GRIN2DGRIN3BADRA1DADRA1A
Trifluoroacetic Acid SCHEMBL25388525 0.87 DRD2 (0.43) DRD2GRIN2DGRIN3BADRA1DADRA1A
SCHEMBL28960982 0.86 GRIN2D (0.51) DRD2GRIN2DGRIN3BADRA1DADRA1A
Tert-Butyl Formate SCHEMBL28818068 0.83 DRD2 (0.40) DRD2GRIN2DGRIN3BADRA1DADRA1A
SCHEMBL16249349 0.82 GRIN2D (0.49) DRD2GRIN2DGRIN3BADRA1DADRA1A
SCHEMBL9135022 0.82 GRIN2D (0.49) DRD2GRIN2DGRIN3BADRA1DADRA1A
SCHEMBL3866792 0.81 ALDH1A1 (0.37) DRD2GRIN2DGRIN3BADRA1DADRA1A
SCHEMBL2989469 0.81 GRIN2B (0.46) GRIN2DGRIN3BADRA1DADRA1AADRA1B
SCHEMBL7298964 0.81 GAA (0.39) DRD2GRIN2DGRIN3BADRA1DADRA1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 261 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260092134-A1 Bioreducible Poly (Beta-Amino Ester)s For siRNA Delivery UNIV JOHNS HOPKINS (US) 2026-04-02 — — US disclosed
US-12527746-B2 Peptide/particle delivery systems THE JOHNS HOPKINS UNIVERSITY (US) 2026-01-20 — — US disclosed
EP-4642434-A2 LIPID COMPOSITIONS ON THE BASIS OF IONIZABLE LIPIDS, USE FOR DELIVERY TO IMMUNE CELLS Life Technologies Corporation (US) 2025-11-05 — — EP disclosed
US-12458700-B2 Amine-containing transfection reagents and methods for making and using same Life Technologies Corporation (US) 2025-11-04 — — US disclosed
US-12371522-B2 Bioreducible poly (beta-amino ester)s for siRNA delivery THE JOHNS HOPKINS UNIVERSITY (US) 2025-07-29 — — US disclosed
US-20250136737-A1 MULTICOMPONENT DEGRADABLE CATIONIC POLYMERS THE JOHNS HOPKINS UNIVERSITY 2025-05-01 — — US disclosed
EP-4472963-A1 DGK TARGETING COMPOUNDS AND USES THEREOF Arvinas Operations, Inc. (US) 2024-12-11 — — EP disclosed
CN-118946556-A DGK targeting compounds and uses thereof 阿维纳斯运营公司 2024-11-12 — — CN disclosed
US-20240263196-A1 Lipid Compositions and Methods for Delivery to Immune Cells Life Technologies Corporation 2024-08-08 — — US disclosed
US-12049530-B2 Multicomponent degradable cationic polymers THE JOHNS HOPKINS UNIVERISTY (US) 2024-07-30 — — US disclosed
EP-0929563-A1 6-O-SUBSTITUTED KETOLIDES HAVING ANTIBACTERIAL ACTIVITY Abbott Laboratories (US) 1999-07-21 — — EP disclosed
WO-1999016779-A1 3'-N-MODIFIED 6-O-SUBSTITUTED ERYTHROMYCIN KETOLIDE DERIVATIVES HAVING ANTIBACTERIAL ACTIVITY ABBOTT LABORATORIES (US) 1999-04-08 — — WO disclosed
US-5889026-A 4-hydroxy-piperodine derivatives HOFFMANN-LA ROCHE INC. (US) 1999-03-30 — — US disclosed
WO-1999011651-A2 3-DESCLADINOSE 6-O-SUBSTITUDED ERYTHROMYCIN DERIVATIVES ABBOTT LABORATORIES (US) 1999-03-11 — — WO disclosed
US-5866549-A MACROLIDE ANTIBIOTICS ABBOTT LABORATORIES (US) 1999-02-02 — — US disclosed
EP-0846683-A1 4-Hydroxy-piperidine derivatives F. HOFFMANN-LA ROCHE AG (CH) 1998-06-10 — — EP disclosed
WO-1998009978-A1 6-O-SUBSTITUTED KETOLIDES HAVING ANTIBACTERIAL ACTIVITY ABBOTT LABORATORIES (US) 1998-03-12 — — WO disclosed
EP-0824098-A1 4-hydroxy-piperidine derivatives F. HOFFMANN-LA ROCHE AG (CH) 1998-02-18 — — EP disclosed
CN-1171396-A 4-hydroxy-piperidine derivatives HOFFMANN LA ROCHE (CH) 1998-01-28 — — CN disclosed
WO-1997042206-A1 6-O-SUBSTITUTED ERYTHROMYCIN COMPOUNDS AND METHOD FOR MAKING SAME ABBOTT LABORATORIES (US) 1997-11-13 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12527746-B2 Peptide/particle delivery systems VEGFA, IGF2BP2, MSTN DRD2 3711/4885GRIN2D 2887/4885GRIN3B 3728/4885
US-20250136737-A1 MULTICOMPONENT DEGRADABLE CATIONIC POLYMERS PEF1, FIBP, PARN DRD2 2399/4885GRIN2D 4425/4885GRIN3B 3777/4885
US-12458700-B2 Amine-containing transfection reagents and methods for making and using same SNRPA, NUDT21, SOAT2 DRD2 2537/4885GRIN2D 4712/4885GRIN3B 2951/4885
US-12371522-B2 Bioreducible poly (beta-amino ester)s for siRNA delivery AARS1, SLC43A1, PHAX DRD2 4287/4885GRIN2D 4708/4885GRIN3B 4153/4885
US-12049530-B2 Multicomponent degradable cationic polymers PEF1, FIBP, PARN DRD2 2399/4885GRIN2D 4425/4885GRIN3B 3777/4885
US-20260092134-A1 Bioreducible Poly (Beta-Amino Ester)s For siRNA Delivery SLC43A1, SLC7A5, SLC7A1 DRD2 4774/4885GRIN2D 3939/4885GRIN3B 4374/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.